UNIGE document Scientific Article
previous document  unige:93702  next document
add to browser collection
Title

mTOR Inhibition & Clinical Transplantation: Pancreas & Islet

Authors
Squifflet, Jean-Paul
Published in Transplantation. 2017
Abstract This brief overview discusses the beneficial and deleterious effects of mTOR inhibitors on beta-cells, and how sirolimus- and everolimus-based immunosuppression have impacted on practices and outcomes of pancreas and islet transplantation. Sirolimus was the cornerstone of immunosuppressive regimens in islet transplantation at the turn of the millenium, but utilization of mTOR inhibitors has progressively decreased from >80% to <50% of islet transplant recipients in more recent years. For whole pancreas transplantation, mTOR inhibitors were used in approximately 20% of patients in the early 2000s, but this dropped over the years to <10% currently. This decrease is arguably due to less well tolerated side effects without the advantage of better outcomes. Nonetheless, mTOR inhibitors remain extremely valuable as second line immunosuppressants in pancreas and islet transplantation.
Identifiers
PMID: 28230643
Full text
Article (Author postprint) (1.4 MB) - private document Private access (until 2018-03-02)
Structures
Research groups La transplantation d'îlots de Langerhans (623)
Transplantation et hépatologie (905)
Citation
(ISO format)
BERNEY, Thierry et al. mTOR Inhibition & Clinical Transplantation: Pancreas & Islet. In: Transplantation, 2017. https://archive-ouverte.unige.ch/unige:93702

15 hits

0 download

Update

Deposited on : 2017-04-21

Export document
Format :
Citation style :